Lv11
58 积分 2023-05-19 加入
Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidance
2小时前
已完结
Bruton Tyrosine Kinase Degraders Current Concepts
10天前
已完结
PROTAC 2.0: Expanding the frontiers of targeted protein degradation
13天前
已完结
Session 5: Protein Degraders
13天前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
13天前
已完结
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders
17天前
已完结
Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies
18天前
已完结
Bruton Tyrosine Kinase Degraders Current Concepts
18天前
已完结
The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects
28天前
已完结
Discovery of TQ-3959 as a Potent and Orally Bioavailable BTK PROTAC Degrader Incorporating a Novel Benzisoxazole-Based CRBN Ligand for the Treatment of B-Cell Malignancies
1个月前
已完结
皖公网安备34019202002308
